COVID-19 future or investigational therapies: Difference between revisions

	COVID-19 Microchapters
Home
Long COVID
Frequently Asked Outpatient Questions
Frequently Asked Inpatient Questions
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating COVID-19 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Vaccines
Secondary Prevention
Future or Investigational Therapies Ongoing Clinical Trials
Case Studies
Case #1
COVID-19 future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of COVID-19 future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on COVID-19 future or investigational therapies
CDC on COVID-19 future or investigational therapies
COVID-19 future or investigational therapies in the news
Blogs on COVID-19 future or investigational therapies
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for COVID-19 future or investigational therapies

Revision as of 18:00, 16 March 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.

The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:


Vaccine Base	Antigen	Clinical Testing	Pros
DNA	Spike protein S1	Phase I, II (NCT03721718)	Reduced production time Easy design and manipulation Stimulates B and T cells responses
Viral Vector	Spike protein S1; Chimpanzee adenovirus vector, Modified Vaccinia Ankara
Conjugated subunit
Virion
Inactivated
Live attenuated

@@ Line 14: / Line 14: @@
 === Prior Work ===
-The following table depicts major vaccine products that have been developed agains SARS-CoV and MERS-CoV:
+The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:
 <br />
 {| class="wikitable"
@@ Line 25: / Line 25: @@
 |-
 |DNA
+|Spike protein S1
+|Phase I, II
+(NCT03721718)
 |
-|
+* Reduced production time
-|
+* Easy design and manipulation
+* Stimulates B and T cells  responses
 |
 |-
 |Viral Vector
-|
+|Spike protein S1; Chimpanzee adenovirus vector,  Modified Vaccinia Ankara
 |
 |